Clinical trial · Observational
Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study involves the use of reagents or materials for diagnostic assessments that are not commercially available, specifically a metabolomic signature for screening endometrial carcinoma and/or other types of cancers, and follows a case-control design. This study aims to achieve several objectives that contribute to evaluating the diagnostic potential of a specific "metabolomic signature" to be used for screening endometrial carcinoma. Specifically, the study seeks to assess the signature's discriminative ability in differentiating between benign endometrial neoplasms and neoplasms of different histological origins.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Carcinoma (EC) | Endometrial Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metabolomic profiling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Cohort of women with endometrial carcinoma
- interventionNames
- Other: Metabolomic profiling
- label
- Cohort of healthy subjects to be used as controls
- interventionNames
- Other: Metabolomic profiling
- label
- Cohort of other non-oncological uterine conditions and oncological conditions affecting other organ
- interventionNames
- Other: Metabolomic profiling
- label
- Additional cohort will be recruited to validate the trained models
- description
- This cohort will consist of postmenopausal women, aged between 50 and 80 years.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 50 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female sex 2. Age between 50 and 80 years 3. Willingness to participate in the study and signing of the informed consent 4. Clinical condition of post-menopause Exclusion Criteria: 1. Previous hysterectomy 2. Hormone replacement therapy 3. Immunosuppressive therapy
References
Publications (0)
Data not yet available